Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Artemether

FDA-approved product (tablet, oral).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Artemether
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Malaria

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Artemisinin and derivatives, plain
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P01BE02; WHO ATC P01BE05

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Artemether, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA39.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli26.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae16.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis22.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Artemether in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Artemether with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • In-vivo Efficacy and Safety of Artemether/Lumefantrine Vs Dihydroartemisinin-piperaquine for Treatment of Uncomplicated Malaria and Assessment of Parasite Genetic Factors Associated With Parasite Clearance or Treatment Failure

    NCT02590627 · start 2014-05

    Registered record
    Registry ID
    NCT02590627
    Conditions
    Malaria
    Interventions
    Artemether-lumefantrine; Dihydroartemisinin-piperaquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-05
    Completion
    2015-12
    Enrolment
    509

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionArtemether-lumefantrine; Dihydroartemisinin-piperaquine
    PhasePhase 4
    Registry statusCompleted

  • Adherence to Antimalarial Drugs in Sierra Leone

    NCT01967472 · start 2013-09-16

    Registered record
    Registry ID
    NCT01967472
    Conditions
    Malaria
    Interventions
    amodiaquine-artesunate (AQAS) fixed-dose; Artemether-lumefantrine combination (AL) dispersable
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-09-16
    Completion
    2014-01
    Enrolment
    1,145

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    Interventionamodiaquine-artesunate (AQAS) fixed-dose; Artemether-lumefantrine combination (AL) dispersable
    PhaseNot applicable
    Registry statusCompleted

  • The Optimal Timing Of Primaquine To Prevent Malaria Transmission After Artemisinin-Combination Therapy

    NCT01906788 · start 2013-05

    Registered record
    Registry ID
    NCT01906788
    Conditions
    Malaria Transmission
    Interventions
    Artemether Lumefantrine; Artemether Lumefantrine 6 dose regimen & single dose of Primaquine on day 0; Artemether Lumefantrine 6 dose regimen and single dose Primaquine on day 2
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2013-05
    Completion
    2013-10
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria Transmission
    InterventionArtemether Lumefantrine; Artemether Lumefantrine 6 dose regimen & single dose of Primaquine on day 0; Artemether Lumefantrine 6 dose regimen and single dose Primaquine on day 2
    PhasePhase 4
    Registry statusUnknown

  • Trial of Malaria Seasonal IPTc Combined With Community Case Management

    NCT01449045 · start 2011-07

    Registered record
    Registry ID
    NCT01449045
    Conditions
    Malaria
    Interventions
    IPTc+CCM; Community Case Management with artemether-lumefantrine (AL)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-07
    Completion
    2012-02
    Enrolment
    4,554

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionIPTc+CCM; Community Case Management with artemether-lumefantrine (AL)
    PhasePhase 3
    Registry statusCompleted

  • Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Vivax in Pregnancy in Brazil (PAACT-PV)

    NCT01107145 · start 2011-02

    Registered record
    Registry ID
    NCT01107145
    Conditions
    Plasmodium Vivax Malaria
    Interventions
    Mefloquine- Artesunate; Artemether-Lumefantrine; Chloroquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2011-02
    Completion
    2012-01
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlasmodium Vivax Malaria
    InterventionMefloquine- Artesunate; Artemether-Lumefantrine; Chloroquine
    PhasePhase 4
    Registry statusTerminated

  • Artemisinin-Based Antimalarial Combinations and Clinical Response in Cameroon

    NCT01845701 · start 2010-03

    Registered record
    Registry ID
    NCT01845701
    Conditions
    Malaria
    Interventions
    Artesunate-Amodiaquine; Dihydroartemisinine-Piperaquine; Artemether-lumefantrine combination
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-03
    Completion
    2015-04
    Enrolment
    720

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionArtesunate-Amodiaquine; Dihydroartemisinine-Piperaquine; Artemether-lumefantrine combination
    PhasePhase 3
    Registry statusCompleted

  • Non-malarial Febrile Illness in Children in Areas of Perennial Malaria Transmission

    NCT01043744 · start 2010-01

    Registered record
    Registry ID
    NCT01043744
    Conditions
    Malaria; Non-malarial Febrile Illness
    Interventions
    Artemether-Lumefantrine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-01
    Completion
    2011-12
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria; Non-malarial Febrile Illness
    InterventionArtemether-Lumefantrine
    PhaseNot applicable
    Registry statusCompleted

  • Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy (TRANSACT)

    NCT00868465 · start 2009-04

    Registered record
    Registry ID
    NCT00868465
    Conditions
    Uncomplicated Malaria
    Interventions
    Artemether-Lumefantrine; Dihydroartemisinin-piperaquine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-04
    Completion
    2010-05
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUncomplicated Malaria
    InterventionArtemether-Lumefantrine; Dihydroartemisinin-piperaquine
    PhaseNot applicable
    Registry statusCompleted

  • Assessment of the Therapeutic Efficacy and Tolerability of the Artesunate/Amodiaquina Combination and Artemether/Lumefantrine Combination, Treatment of Uncomplicated P. Falciparum Malaria in the Department of Chocó (Colombia)

    NCT04877626 · start 2008-09

    Registered record
    Registry ID
    NCT04877626
    Conditions
    P. Falciparum Malaria
    Interventions
    Artemeter plus lumefantrina vs artesunato plus amodiquina
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-09
    Completion
    2009-12
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionP. Falciparum Malaria
    InterventionArtemeter plus lumefantrina vs artesunato plus amodiquina
    PhasePhase 4
    Registry statusCompleted

  • Treatment of Non-falciparum Malaria

    NCT00725777 · start 2008-07

    Registered record
    Registry ID
    NCT00725777
    Conditions
    Acute Non-falciparum Malaria
    Interventions
    artemether-lumefantrine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-07
    Completion
    2012-02
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Non-falciparum Malaria
    Interventionartemether-lumefantrine
    PhaseNot applicable
    Registry statusCompleted

  • Cohort Study in Uganda Comparing Artesunate + Amiodaquine (Coarsucam) Versus Artemether + Lumenfantrine (Coartem) in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks

    NCT00699920 · start 2008-06

    Registered record
    Registry ID
    NCT00699920
    Conditions
    Malaria
    Interventions
    Coarsucam; Coartem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-06
    Completion
    2010-06
    Enrolment
    413

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionCoarsucam; Coartem
    PhasePhase 4
    Registry statusCompleted

  • Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients

    NCT00620438 · start 2008-02

    Registered record
    Registry ID
    NCT00620438
    Conditions
    HIV Infections; Tuberculosis
    Interventions
    Lumefantrine-artemether and nevirapine; lumefantrine-artemether and efavirenz; Lumefantrine-artemether and rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2008-02
    Completion
    2011-07
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Tuberculosis
    InterventionLumefantrine-artemether and nevirapine; lumefantrine-artemether and efavirenz; Lumefantrine-artemether and rifampicin
    PhasePhase 4
    Registry statusUnknown

  • Zambia Integrated Management of Malaria and Pneumonia Study

    NCT00513500 · start 2007-06

    Registered record
    Registry ID
    NCT00513500
    Conditions
    Pneumonia; Malaria
    Interventions
    Coartem and amoxicillin; Coartem
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-06
    Completion
    2009-09
    Enrolment
    3,125

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia; Malaria
    InterventionCoartem and amoxicillin; Coartem
    PhaseNot applicable
    Registry statusCompleted

  • Effectiveness of Artemether-Lumefantrine for Malaria Treatment of Children at Community Level in Tanzania

    NCT00454961 · start 2007-04

    Registered record
    Registry ID
    NCT00454961
    Conditions
    Malaria
    Interventions
    artemether-lumefantrine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-04
    Completion
    Not recorded
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    Interventionartemether-lumefantrine
    PhasePhase 4
    Registry statusCompleted

  • Quinine vs. Artemether/Lumefantrine in Uncomplicated Malaria During Pregnancy

    NCT00495508 · start 2006-10

    Registered record
    Registry ID
    NCT00495508
    Conditions
    Malaria
    Interventions
    Quinine; artemether / lumefantrine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-10
    Completion
    2009-06
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionQuinine; artemether / lumefantrine
    PhasePhase 4
    Registry statusCompleted